Programme at a glance | Plenary Program | Keynote and Plenary Speakers | IPOS Early Career Professionals Events
IPOS Academy Workshops

Keynote and Plenary Speakers

Tatsuo Akechi
  Usefulness of smartphone behavioral activation and problem-solving treatment on fear of recurrence

Tatsuo Akechi, MD, PhD, Professor, Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences & Director, Division of Psycho-Oncology and Palliative Care, Nagoya City University Hospital, Nagoya, Japan

Dr. Tatsuo Akechi graduated from Hiroshima University School of Medicine in 1991 and now is a Professor of Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences in Japan since 2011. He is also the President of Japan Psycho-oncology Society since 2015. His major areas of work/interests are depression and suicidality among cancer patients and psychosocial intervention for cancer patients.
Susanne Dalton
  Social inequalities in survivorship

Susanne Dalton is a Senior Researcher and head of the Research Group on Social Inequality in Survivorship, Danish Cancer Society Research Center. She investigates the influence of social circumstances on cancer outcomes and life after cancer for patients and their family. She conducts large-scale population-based studies using registry data and/or questionnaire data and she develop and test psychosocial interventions to improved treatment and late effects among vulnerable cancer patients or patients at special risk for developing late effects. Through her career SD has collaborated with national and international clinical and academic researchers.

She graduated as an MD in 1998 and received her PhD on depression and cancer in 2002. She has published more than 170 peer-reviewed papers in international scientific journals, several book chapters and she is involved in organizing several international conferences, strategic international and national scientific funding committees and editorial boards of scientific journals.

Within IPOS, she has been facilitating Academy workshops since 2011 on research methodology and in 2015 she received the Bernard Fox Memorial Award.
CK Fang
  Advancing progress in palliative care

Present Employments
  • Chief, Department of Psychiatry, Mackay Memorial Hospital, Taipei, Taiwan
  • Chief, Suicide Prevention Center, Mackay Memorial Hospital, Taipei, Taiwan
  • Council Member, Academy of Asia Hospice Palliative Medicine
  • Chairman, Asia-Pacific Psycho-Oncology Exchange Foundation
  • President, Taiwan Association for Caring and Counseling for Loss
  • Executive director, Taiwan Psycho-Oncology Society
  • Board, Taiwan Hospice Organization
  • Board, Taiwan Academy of Hospice Palliative Medicine
  • Board, Taiwan Society of Psychiatry
  • Board, Taiwan Association Against Depression
  • Board, Taiwan Transactional Analysis Association
  • Assistant Professor, Department of Medicine and Department of Nursing, Mackay Medical College


  • Psychiatry, Psycho-Oncology, Hospice Palliative Medicine, Suicidology, Life and death studies, Substance abuse treatment, Spiritual care

Academic Background

  • Bachelor: Department of Chinese Medicine, China Medical University, Taichung, Taiwan. (1988/9~1995/6)
  • Master: Institute of Life and Death Education and Counseling, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan. (2003/8~2005/6)
  • Ph.D. candidate: Department of Biomedical Imaging and Radiological Sciences (BIRS), National Yang-Ming University, Taipei, Taiwan. (2008/9~2013/6)


  • Visiting Fellow: Australian Institute for Suicide Research and Prevention, Griffith University, Brisbane, Queensland, Australia.(2006/7~2006/8)


  • 2017 Noemi Fisman Award for Lifetime Clinical Excellence Recipient

International Individual Membership

  • International Work Group on Death, Dying and Bereavement (IWG), invited guest.
  • International Psycho-Oncology Society (IPOS)
  • Association for Death Education and Counseling (ADEC)
  • Asia-Pacific Hospice Palliative Care Network (APHN)
Ednin Hamzah    
  Advanced and end-stage disease in Asia

Dr Ednin Hamzah is the Chief Executive Officer of Hospis Malaysia, a position he has held from 1997. Dr Ednin graduated in medicine from the University of Newcastle upon Tyne, United Kingdom in 1986 and had worked in internal and family medicine in the United Kingdom prior to returning to Malaysia in 1997.

Clinically, he leads the largest community palliative care service in Malaysia. He teaches palliative care in several universities at both undergraduate and postgraduate levels. Nationally he has been involved in palliative care, cancer and pain development and has been on the Boards of several National Organisations. He is active in international palliative care education and advocacy and is the current Vice Chairman of the Asia Pacific Hospice Palliative Care Network and a member of the Board of Trustees for the Worldwide Hospice Palliative Care Alliance.
Paul Jacobsen
  Inequalities in cancer care

Paul Jacobsen received his doctoral degree in Psychology from Michigan State University and completed post-doctoral training in psychosocial oncology at Memorial Sloan Kettering Cancer Center. He was subsequently recruited to the Moffitt Cancer Center in Tampa, Florida where he served as founding Chair of the Department of Health Outcomes and Behavior and later as Associate Center Director for Population Science. For over 30 years, his research has focused on using knowledge from the behavioral and social sciences to understand and address quality of life and quality of care issues related to the diagnosis and treatment of cancer. Dr. Jacobsen is the author of more than 300 journal articles and has been the recipient of numerous research grants from the American Cancer Society and the (U.S.) National Cancer Institute. In 2016, he entered public service as the Associate Director in the National Cancer Institute’s Division of Cancer Control and Population Science where he directs the Healthcare Delivery Research Program. In this position, he leads a team whose mission is to advance innovative research to improve the delivery of cancer care. He also plays a key role in National Cancer Institute’s collaborations with other agencies and organizations involved in health services and outcomes research.
Liz Lobb
  Late stage disease and end of life care

Liz Lobb is Professor of Palliative Care (Allied Health) based at Calvary Health Care Kogarah, and is an Adjunct Professor in the Faculty of Medicine at the University of Notre Dame, Sydney and the Faculty of Health at the University of Technology, Sydney.  Professor Lobb obtained her PhD in Psychological Medicine from the Faculty of Medicine at the University of Sydney in 2001. She has worked clinically as a bereavement counsellor and educator for 24 years. In addition, as a behavioural scientist, Liz has worked in psycho-oncology and palliative care research for 21 years. She has established national and international research collaborations and pursued independent multi-disciplinary clinical collaborations in oncology, haematology, cancer genetics and palliative care. This research has enhanced evidence based communication and psycho-social care across the cancer continuum from diagnosis, through treatment, remission and survivorship or relapse, palliative care and bereavement support for families and caregivers.
Tony Mok
  Translational therapeutics in lung cancer - implications for improving care


Professor Tony S.K. Mok was trained at the University of Alberta, Canada and he subsequently completed a fellowship in medical oncology at the Princess Margaret Hospital in Canada. After working as a community oncologist in Toronto, Canada for seven years, he returned to Hong Kong in 1996 to pursue an academic career.

Professor Mok is the Li Shu Fan Medical Foundation endowed Professor and Chairman of Department of Clinical Oncology at the Chinese University of Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He was the Principal Investigator and first author on the landmark IRESSA® Pan-Asia Study (IPASS), which was the first study that confirmed the application of precision medicine for advanced lung cancer. He has also led and co-led multiple studies including the FASTACT 2, IMPRESS, ARCHER 1050, ALEX and AURA 3. These projects address various aspects on management of EGFR mutation positive lung cancer, and basically have defined the current practice. He dedicates his work on precision medicine for lung cancer by also engaging in clinical research on ALK positive lung cancer and immunotherapy. The series of clinical trials, led or co-led by Professor Mok, have defined precision medicine for lung cancer. His work has been adopted by multiple international guidelines including NCCN, AMP/IASLC/CAP, ASCO and ESMO. He also contributes to the development of clinical research infra-structure in China and Asia. He cofounded the Lung Cancer Research Group, Chinese Thoracic Oncology Research Group and Asia Thoracic Oncology Research Group.

Professor Mok has contributed to over 220 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet and Journal of Clinical Oncology, and contributed to multiple editorials and textbooks. He is an Associate Editor for thoracic oncology for the Journal of Clinical Oncology and other international journals. He is the Past President and Current Treasurer of the International Association for the Study of Lung Cancer (IASLC). He serves on ASCO Board of Directors from 2018 to 2022. He is active in international education activity and has made significant contribution to AACR, ASCO, CSCO and ESMO. His work was recognized by numerous awards including Bonnie Addario Award in 2015, Fellowship of the American Society of Clinical Oncology (FASCO) in 2017, Paul Bunn Jr Scientific Award in 2017 and National Science and Technology Progress Award in 2017.  His recent article in the New England Journal of Medicine has been selected as one of the most “Notable Articles in 2017.”

Nicole Rankin
  Translational research

Dr Nicole Rankin is an implementation scientist and Senior Research Fellow at Cancer Council NSW in lung cancer, and Senior Lecturer in Implementation Science, University of Sydney. Nicole has a PhD in Behavioural Science in Relation to Medicine from the University of Newcastle, Australia. Prior to joining the Cancer Council NSW in February 2017, Nicole was Senior Research Fellow at Sydney Catalyst Translational Cancer Research Centre, University of Sydney, for six years.

Nicole is leading innovative programs in lung cancer research and in implementation science education for researchers and health professionals. In the ‘Pathways to a Cancer Free Future - Lung Cancer’ program at Cancer Council NSW, her work focuses on intervention development, implementation and translation across the areas of screening, early detection and psychosocial and palliative care. The program team will assess the best value interventions to improve lung cancer incidence, mortality and quality of life through a unique combination of statistical projections and modelling, systematic reviews and implementation research, and in consultation with key stakeholders.

In 2016, Nicole commenced a two-year fellowship in the Mentored Training in Dissemination and Implementation Research in Cancer (MT-DIRC) program at Washington University in St Louis. She brings her expertise in psycho-oncology, qualitative research, clinical practice guideline development and the translation of evidence into policy and practice, to numerous collaborations and projects in Australia and internationally.
William Redd
  Light therapy for symptom control

For more than 35 years William Redd has been engaged in research on psychosocial-oncology and cancer prevention and control. He is credited for introducing behavioral psychology and behavioral medicine to research and clinical practice in cancer supportive care. His most recent research on controlling cancer-related fatigue has drawn considerable attention. Redd received the Arthur M. Sutherland Lifetime Achievement Award from the International Psycho-Oncology Society in 2015. He has had continuous NIH research support over the last two decades. His current research examines: 1) the contribution of circadian rhythm disruption in cancer-related somatic and behavioral problems, 2) the role of systematic light exposure to ameliorate negative sequela of cancer and its treatment and 3) modification of environmental illumination to improve health and quality of life. Redd’s mission is to apply behavioral principles to understand and treat negative sequela of cancer and its treatment.
Deborah Schrag
  Symptom monitoring and outcomes

Deborah Schrag, MD, MPH, a medical oncologist and health services researcher at the Dana Farber Cancer Institute and Professor of Medicine at Harvard Medical School. She serves as the Chief of the Division of Population Sciences within the Department of Medicine at Dana Farber.

Dr. Schrag earned her medical degree from Columbia University College of Physicians and Surgeons and her master’s degree in public health from the Harvard School of Public Health.  She completed her residency in internal medicine at Brigham and Women’s Hospital and a fellowship in medical oncology at Dana-Farber. From 1998-2007, she practiced medical oncology in the Division of Gastrointestinal Oncology at Memorial Sloan-Kettering Cancer Center, where she was an associate professor of public health and medicine. In 2008, she returned to Dana-Farber, where she has focused her research on evaluating and improving the quality and effectiveness of cancer care delivery.  This includes an emphasis on remediation of health care disparities. Her work has focused on cancer care delivery in the Medicaid population with attention to remediation of disparities based on race, socioeconomic position and access to specialty health care. Recent work focuses on access to precision medicine and high cost anti-neoplastic therapy. Her research portfolio is funded by NCI, AHRQ, and PCORI.
Lili Tang
  Implementing out-patient care for late stage disease in China

Medical Director,  M.D & PhD Candidate Supervisor
The Director of the Dept. of Psycho-Oncology
Peking University Cancer Hospital
President, Chinese Psycho-Oncology Society (CPOS)
President, Beijing Psycho-Oncology Society
Vice-President,  Chinese Geriatric Oncology Society
Palliative Care Committee
Vice-President,  Society Rehabilitation and Palliative Care Committee
Vice-President, China Association for Mental Health Psychosomatic Medicine Committee